Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

OUEST PHARMA HOLDING : revenue, balance sheet and financial ratios

OUEST PHARMA HOLDING is a French company founded 4 years ago, specialized in the sector Autres intermédiaires du commerce en produits divers. Based in MEZIERES-LEZ-CLERY (45370), this company of category PME shows in 2024 a net income positive of 275 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - OUEST PHARMA HOLDING (SIREN 901564062)
Indicator 2024 2023 2022 2021
Revenue N/C N/C N/C N/C
Net income 275 358 € 106 743 € 93 026 € -50 €
EBITDA -1 595 € -6 489 € -989 € -50 €
Net margin N/C N/C N/C N/C

Revenue and income statement

In 2024, OUEST PHARMA HOLDING generates positive net income of 275 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-1 595 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-1 595 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

275 358 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 5%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 93%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.1 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

4.592%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

93.423%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.127

Solvency indicators evolution
OUEST PHARMA HOLDING

Sector positioning

Debt ratio
4.59 2024
2022
2023
2024
Q1: 0.0
Med: 6.15
Q3: 45.95
Good -7 pts over 3 years

In 2024, the debt ratio of OUEST PHARMA HOLDING (4.59) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
93.42% 2024
2022
2023
2024
Q1: 3.97%
Med: 34.0%
Q3: 67.32%
Excellent

In 2024, the financial autonomy of OUEST PHARMA HOLDING (93.4%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.13 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.0 years
Q3: 0.8 years
Average

In 2024, the repayment capacity of OUEST PHARMA HOLDING (0.13) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 1703.83. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

1703.826

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-48.276

Liquidity indicators evolution
OUEST PHARMA HOLDING

Sector positioning

Liquidity ratio
1703.83 2024
2022
2023
2024
Q1: 139.4
Med: 252.5
Q3: 584.37
Excellent

In 2024, the liquidity ratio of OUEST PHARMA HOLDING (1703.83) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
-48.28x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.0x
Q3: 0.95x
Watch

In 2024, the interest coverage of OUEST PHARMA HOLDING (-48.3x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 587 days. Excellent situation: suppliers finance 587 days of the operating cycle (retail model).

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

587 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
OUEST PHARMA HOLDING

Positioning of OUEST PHARMA HOLDING in its sector

Comparison with sector Autres intermédiaires du commerce en produits divers

Valuation estimate

Based on 85 transactions of similar company sales (all years), the value of OUEST PHARMA HOLDING is estimated at 378 082 € (range 180 278€ - 1 938 498€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2024
85 tx
180k€ 378k€ 1938k€
378 082 € Range: 180 278€ - 1 938 498€
NAF 5 all-time

Valuation method used

Net Income Multiple
275 358 € × 1.4x = 378 083 €
Range: 180 279€ - 1 938 498€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 85 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Autres intermédiaires du commerce en produits divers)

Compare OUEST PHARMA HOLDING with other companies in the same sector:

Voir toutes les statistiques du secteur Autres intermédiaires du commerce en produits divers

Frequently asked questions about OUEST PHARMA HOLDING

What is the revenue of OUEST PHARMA HOLDING ?

The revenue of OUEST PHARMA HOLDING is not publicly disclosed (confidential accounts filed with INPI).

Is OUEST PHARMA HOLDING profitable?

Yes, OUEST PHARMA HOLDING generated a net profit of 275 k€ in 2024.

Where is the headquarters of OUEST PHARMA HOLDING ?

The headquarters of OUEST PHARMA HOLDING is located in MEZIERES-LEZ-CLERY (45370), in the department Loiret.

Where to find the tax return of OUEST PHARMA HOLDING ?

The tax return of OUEST PHARMA HOLDING is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does OUEST PHARMA HOLDING operate?

OUEST PHARMA HOLDING operates in the sector Autres intermédiaires du commerce en produits divers (NAF code 46.19B). See the 'Sector positioning' section above to compare the company with its competitors.